Does the clinical efficacy of vardenafil correlate with its effect on the endothelial function of cavernosal arteries? A pilot study
Authors:
- 9 October 2006
- journal article
- Published by Wiley in BJU International
- Vol. 98 (5) , 1054-1058
Abstract
OBJECTIVE: To investigate whether the results of the ultrasonographic (US) measurement of post‐occlusive changes in the diameters of cavernosal arteries after administering phosphodiesterase type 5 (PDE‐5) inhibitor vardenafil could be associated with the response to vardenafil in patients with erectile dysfunction (ED), as currently there are no reliable methods for predicting the success rate of oral PDE‐5 inhibitors. PATIENTS AND METHODS: The study included 122 men with ED; after a complex evaluation, the endothelial function of the cavernosal arteries was assessed in all patients before and 1 h after oral ingestion of vardenafil (20 mg), using our modification of the US assessment of post‐occlusive changes in the diameter of cavernosal arteries. After the evaluation, all patients received vardenafil 20 mg on demand for 4 weeks. A successful response was defined using two endpoints, i.e. the normalization of the International Index of Erectile Function Erectile Function domain score (≥26) and positive answers to both Sexual Encounter Profile questions 2 and 3 on ≥ 75% of occasions, based on the diary data collected. RESULTS: In all patients the mean ( sd ) initial percentage increase in the cavernosal artery diameter (PICAD) in responders and nonresponders was not statistically different, at 49 (24) and 43 (26), respectively ( P = 0.168), but PICAD values after vardenafil were significantly greater in responders, at 73 (16) vs 55 (23) ( P < 0.001). Analysis of data from patients with different causes of ED showed statistically significant differences in PICAD between responders and nonresponders only in those with arteriogenic ED. The sensitivity and specificity of a PICAD of ≥ 50% after taking vardenafil 20 mg for predicting a positive response to the same dose of the drug in patients with arteriogenic ED were 94.9% and 91.3%, respectively. CONCLUSION: The results of the US assessment of post‐occlusive changes in the diameter of cavernosal arteries after vardenafil administration are significantly associated with the clinical efficacy of the drug in patients with arteriogenic ED.Keywords
This publication has 23 references indexed in Scilit:
- Testing Endothelial Function of Brachial and Cavernous Arteries in Patients with Erectile DysfunctionThe Journal of Sexual Medicine, 2006
- Vardenafil in Patients With Erectile Dysfunction: Achieving Treatment OptimizationJournal of Andrology, 2005
- Chronic Treatment with Tadalafil Improves Endothelial Function in Men with Increased Cardiovascular RiskEuropean Urology, 2005
- Sildenafil Citrate Response Correlates with the Nature and the Severity of Penile Vascular InsufficiencyThe Journal of Sexual Medicine, 2005
- Vardenafil is effective and well‐tolerated for treating erectile dysfunction in a broad population of men, irrespective of ageBJU International, 2004
- Efficacy of Sildenafil Citrate in Treatment of Erectile Dysfunction: Effect of Type 2 DiabetesEuropean Urology, 2004
- The efficacy and safety of tadalafil: an updateBJU International, 2004
- Acute and Prolonged Effects of Sildenafil on Brachial Artery Flow-Mediated Dilatation in Type 2 DiabetesDiabetes Care, 2002
- IMPROVING THE ACCURACY OF VASCULAR TESTING IN IMPOTENT MEN:Journal of Urology, 2001
- GENITAL PLUS AUDIOVISUAL SEXUAL STIMULATION FOLLOWING INTRACAVERNOUS VASOACTIVE INJECTION VERSUS RE-DOSING FOR ERECTILE DYSFUNCTION-RESULTS OF A PROSPECTIVE STUDYJournal of Urology, 1998